Previous 10 | Next 10 |
BLD,BRSP,CBRL,CEQP,CFX,CNP,DFIN,ESPR,ETRN,EXPD,FLR,HD,HEP,HL,HR,KBR,LPX,M,MDT,MIDD,NOVN,NSA,NXST,SBRA,SOHU,TPB,TPX,TRU,WLK,WLKP For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open
DURHAM, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2021 financial results on Tuesday, February 22 nd . Novan management will host a conference call and live ...
DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company’s completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel (previously referred to as SB206) for...
– Live moderated video webcast discussion among management and Pediatric Dermatology Thought Leader on Wednesday, November 17 th at 1:00 PM ET – DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan...
Novan, Inc. (NOVN) Q4 Fiscal Earnings Conference Call November 10, 2021, 8:30 AM ET Company Participants David Auld – CEO Jessica Hansen – Vice President of Investor Mike Murray – Executive Vice President and Co-Chief Operating Officer Bill Wheat – Executive Vice P...
Novan (NASDAQ:NOVN): Q3 GAAP EPS of -$0.34 beats by $0.08. Revenue of $0.74M (-43.9% Y/Y) misses by $0.01M. Press Release For further details see: Novan EPS beats by $0.08, misses on revenue
– Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum – – Advancing priority development pipeline assets by progressing...
Novan (NASDAQ:NOVN) is scheduled to announce Q3 earnings results on Wednesday, November 10th, before market open. The consensus EPS Estimate is -$0.43 and the consensus Revenue Estimate is $0.75M (-43.2% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downw...
ACST, OTCQX:ADDYY, ADNT, AER, AFMD, OTCPK:ALIZF, ALT, ARCO, ASC, ATXS, AY, BTAI, BWEN, DTIL, OTCPK:EMRAF, ENR, EOSE, EVGO, FOUR, FVRR, OTCQX:GDNSF, GIB, GMAB, GSL, OTCQX:IFNNY, INVZ, IS, KIO, KRNT, LODE, MCRB, ME, ML, MNDY, MOGO, MSGS, NEON, NMM, NOVN, OTIC, PDSB, OTCPK:PEYUF, PFGC, PRGO, PTE...
– Data indicate that intranasal administration of SB019 formulation containing berdazimer sodium is well-tolerated and safe under the conditions of preclinical study – – Company believes the promising conclusions from this Good Laboratory Practices (GLP) study...
News, Short Squeeze, Breakout and More Instantly...
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6...
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress ...